首页> 外文期刊>Medicine. >Efficacy and safety of intravenous thrombolysis with alteplase for treating acute ischemic stroke at different time windows: A protocol for systematic review and meta-analysis
【24h】

Efficacy and safety of intravenous thrombolysis with alteplase for treating acute ischemic stroke at different time windows: A protocol for systematic review and meta-analysis

机译:不同时间窗口静脉溶栓治疗急性缺血性脑卒中的疗效和安全性:系统评价和荟萃分析的协议

获取原文
           

摘要

Background: As the priority drug for treating acute ischemic stroke (AIS), alteplase is a thrombolytic drug with strong fibrin specificity. It can obviously treat AIS with high safety. However, the validity of its time window is controversial. This study focus on the efficacy and safety of intravenous thrombolysis with alteplase for treating AIS at different time windows. Methods: Retrieval of English database (PubMed, Embase, Web of Science, the Cochrane Library) and Chinese database was conducted (China National Knowledge Infrastructure, WAN FANG, VIP, China Biology Medicine disc) by computers. From the establishment of the database to October 2020, a retrospective study and case-control study on intravenous thrombolysis at different time windows for treating AIS were conducted. Two researchers independently conducted data extraction and quality evaluation of literature on the included studies, and RevMan5.3 was used for Meta-analysis on the included literature. Results: This study aims to evaluate the efficacy and safety of intravenous thrombolysis with alteplase at different time windows for treating AIS by National Institutes of Health Stroke Scale score, modified Rankin Scale rating scale, spontaneous intracerebral hemorrhage incidence rate, All-cause mortality, and so on. Conclusions: This study will provide an evidence-based basis for the clinical efficacy of alteplase for treating AIS by thrombolytic therapy at different time windows. Ethics and dissemination: Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences.
机译:背景:作为治疗急性缺血性卒中(AIS)的优先药,Alteplase是一种具有强纤维蛋白特异性的溶栓药。它可以显然可以用高安全性治疗AIS。但是,其时间窗口的有效性是有争议的。本研究重点是静脉溶栓与异层溶栓治疗不同时间窗口的疗效和安全性。方法:通过计算机进行英语数据库(PubMed,Embase,Scient,Cope,Cochrane图书馆)和中国数据库的中文数据库(中国知识基础设施,WAN Fang,VIP,中国生物学医学盘)。从数据库到10月20日的建立,进行了对治疗AIS的不同时间窗口静脉内溶栓的回顾性研究和病例研究。两位研究人员独立开展了在内的研究中对文献的数据提取和质量评估,Revman5.3用于除了包括的文献中的Meta分析。结果:本研究旨在评估静脉溶栓在不同时间窗口中静脉溶栓的疗效和安全性,用于治疗AIS,用于治疗AIS,用于治疗AIS,以治疗国家卫生冲程量表评分,改进的Rankin规模评级规模,自发性脑出血发生率,全导致死亡率和很快。结论:本研究将为Alteplase在不同时间窗口溶栓治疗治疗AIS的临床疗效提供基于循证基础。道德和传播:来自个人的私人信息不会出版。该系统审查也不涉及危及参与权。不需要道德批准。结果可以在同行评审期刊中公布或在相关会议上传播。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号